BioCryst Pharmaceuticals, Inc. (BCRX) 2024 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning and welcome to the BioCryst first quarter 2024 earnings call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

    早安,歡迎參加 BioCryst 2024 年第一季財報電話會議。(接線員指示) 請注意,本活動將被錄音。現在我想把會議交給 BioCryst 的 John Bluth。請開始。

  • John Bluth - IR Contact Officer

    John Bluth - IR Contact Officer

  • Thanks, Drew. Good morning and welcome to BioCryst's first quarter 2024 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we will answer your questions.

    謝謝你,Drew。早安,歡迎參加 BioCryst 2024 年第一季公司營運更新與財務結果電話會議。今日新聞稿及隨附簡報投影片已公布於我們的網站。今天與我一同出席的有執行長 Jon Stonehouse;財務長 Anthony Doyle;首席商務長 Charlie Gayer;以及研發長 Helen Thackray 博士。在我們發言之後,我們將回答各位的提問。

  • Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation.

    在開始之前,請注意今天的電話會議將包含前瞻性陳述,包括關於未來結果、未經審計及前瞻性的財務資訊,以及公司未來表現及/或成就的陳述。這些陳述受已知與未知的風險與不確定性影響,可能導致我們的實際結果、表現或成就與本簡報中明示或暗示的任何未來結果或表現有重大差異。

  • You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website.

    您不應過度依賴這些前瞻性陳述。如需更多資訊(包括我們風險因素的詳細討論),請參閱公司向美國證券交易委員會提交的文件,亦可於我們網站查閱。

  • In addition, today's conference call includes non-GAAP pro forma financial measures. For reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release posted in the Press Releases section of our Investor Relations website at www.biocryst.com.

    此外,今天的電話會議包含非 GAAP 的備考(pro forma)財務衡量指標。如需將這些非 GAAP 指標與最直接可比的 GAAP 財務指標進行調節(reconciliation),請參閱發布於我們投資人關係網站(www.biocryst.com)「新聞稿」專區的財報新聞稿。

  • I'd now like to turn the call over to Jon Stonehouse.

    現在我想把電話會議交給 Jon Stonehouse。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Thanks, John. We are off to a fantastic start to the year with growing ORLADEYO revenue and our pipeline advancing on schedule. ORLADEYO revenue in Q1 exceeded our expectations as the commercial team in the US did a great job successfully navigating the reauthorization process faster than previous years. Charlie will share more detail, but now in the fourth year since approval, the steady and consistent growth of new patients shows no signs of letting up and we are even more confident we are on track to reach our goal of $1 billion in global revenue at peak.

    謝謝你,John。今年我們開局非常出色,ORLADEYO 營收持續成長,且我們的產品線(pipeline)也按計畫推進。第一季 ORLADEYO 營收超出我們預期,因為美國商業團隊在處理續授權(reauthorization)流程方面表現優異,速度比往年更快。Charlie 會分享更多細節;但目前距離核准已進入第四年,新病患穩定且持續的成長沒有放緩跡象,我們對於達成全球營收高峰(peak)10 億美元的目標更具信心。

  • We continue to make great progress with our prioritized pipeline too. Our ORLADEYO pediatric program is on schedule to file for approval next year. We continue to make progress with BCX10013 and expect we will be able to decide on whether to partner or discontinue the program later this year. In addition, our other pipeline programs, including BCX17725 for Netherton and avoralstat for DME are advancing toward the clinic with first or best-in-class profiles.

    我們在優先排序的產品線方面也持續取得重大進展。我們的 ORLADEYO 兒科計畫進度如期,預計明年提出核准申請。我們持續推進 BCX10013,並預期今年稍晚可決定是否尋求合作夥伴或終止該計畫。此外,我們其他產品線計畫(包括用於 Netherton 的 BCX17725,以及用於 DME 的 avoralstat)也正以同類首創或同類最佳(first- or best-in-class)的特性朝臨床階段推進。

  • Over the next 12 months, ORLADEYO will be approaching the midway point of our global peak revenue goal. We'll be preparing to file for approval for ORLADEYO use in pediatric patients and we'll be starting to move multiple pipeline programs into patient studies. And last but not least, we will be approaching profitability.

    在未來 12 個月內,ORLADEYO 將接近我們全球營收高峰目標的中點。我們將準備提交 ORLADEYO 用於兒科病患的核准申請,並將開始推動多個產品線計畫進入病患研究。最後但同樣重要的是,我們將逐步接近獲利。

  • The year is off to a strong start with exceptional progress in all of these areas, and we are focused on continuing this momentum throughout the year.

    今年開局強勁,在上述各方面都取得卓越進展;我們將專注於在全年持續延續這股動能。

  • With that, I'll turn it over to Charlie to share the outstanding performance of ORLADEYO for the quarter.

    接下來我把時間交給 Charlie,分享本季 ORLADEYO 的傑出表現。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Thanks, Jon. During the quarter, we continued to execute our global plan for ORLADEYO very effectively. Revenue of $88.9 million exceeded our expectations because of the efficient handling of prescription reauthorizations in the United States, combined with the continued strong demand as health care providers gained confidence in ORLADEYO. Based on these improvements and trends, we are raising our 2024 ORLADEYO revenue guidance to the top half of our prior range and now forecast $390 million to $400 million for the year. I'll describe these improvements and trends more specifically.

    謝謝你,Jon。本季我們持續非常有效地執行 ORLADEYO 的全球計畫。營收達 8,890 萬美元,超出我們預期,原因在於美國處方續授權處理效率提升,加上醫療照護提供者對 ORLADEYO 的信心增加,需求持續強勁。基於這些改善與趨勢,我們將 2024 年 ORLADEYO 營收指引上調至先前區間的上半部,並將全年預測調整為 3.90 億至 4.00 億美元。我將更具體說明這些改善與趨勢。

  • Last year, we invested in our patient services and market access teams with the goal of improving efficiency and effectiveness of patients to paid therapy. The first quarter shows that these investments are working. Two facts stand out in this improvement. First, our patient services team completed more benefits investigations in January than we did in the entire first quarter of 2023, resulting in patients getting back to paid therapy quicker than in previous years.

    去年,我們投資於病患服務與市場准入(market access)團隊,目標是提升病患從啟動到轉為付費治療(paid therapy)的效率與成效。第一季顯示這些投資正在發揮效果。這項改善有兩個重點事實特別突出。第一,我們的病患服務團隊在 1 月完成的保險給付調查(benefits investigations)數量,超過 2023 年第一季整季的完成量,使病患比往年更快回到付費治療。

  • Completing these investigations early in the first quarter gives our better understanding of the ease or difficulty of the reauthorization process. If it's easy, we get to paid shipments quickly. If it's going to be difficult, the team can act faster with better information to solve any issues. And second, even though we still provided temporary free product for many patients during the first quarter reauthorizations, the faster actions in the quarter meant that paid shipments were within 1% of fourth quarter 2023 paid shipments. This was above our expectations.

    在第一季初期就完成這些調查,讓我們能更了解續授權流程的容易或困難程度。若流程容易,我們就能快速轉為付費出貨。若預期會較困難,團隊也能在資訊更充分的情況下更快採取行動,解決任何問題。第二,儘管在第一季續授權期間我們仍為許多病患提供暫時性的免費產品,但本季更快速的處理使付費出貨量與 2023 年第四季的付費出貨量差距在 1% 以內。這高於我們的預期。

  • As for customer demand, we had another very strong quarter for new patient prescriptions. In fact, the last two quarters have been the best consecutive quarters for demand since the six months of the launch in 2021. Patients and health care providers continue to understand and gain confidence that they can get great efficacy and convenience with ORLADEYO, all with just one capsule once a day to prevent HAE attacks.

    就客戶需求而言,新病患處方量本季再次非常強勁。事實上,過去兩季是自 2021 年上市後前六個月以來,需求表現最好的連續兩季。病患與醫療照護提供者持續理解並更有信心:ORLADEYO 只需每日一次、一顆膠囊,即可在預防 HAE 發作方面兼具良好療效與便利性。

  • We also continued to strengthen the brand by presenting new evidence showing the real-world impact of ORLADEYO. At AAAAI in February, we showed how well ORLADEYO is controlling HAE attacks, regardless of prior therapies or baseline attack rates.

    我們也持續透過發表新證據來強化品牌,展示 ORLADEYO 在真實世界中的影響。在 2 月的 AAAAI 會議上,我們展示了 ORLADEYO 在控制 HAE 發作方面的良好表現,不受既往治療或基線發作率影響。

  • Patients switching to ORLADEYO from other HAE prophylaxis therapies, for example, maintain and even improve long-term attack control, reaching a median rate of half an attack per month. Patients attack-free at baseline remained attack-free on ORLADEYO. Later this week, we will present new data at the ISPOR conference in Atlanta, demonstrating that patients initiating ORLADEYO experienced significant reductions in overall health care resource utilization, a finding that will be very meaningful to payers.

    例如,從其他 HAE 預防性治療轉換至 ORLADEYO 的病患,能維持甚至改善長期的發作控制,中位數達到每月 0.5 次發作。在基線即無發作的病患,使用 ORLADEYO 後仍維持無發作。本週稍晚,我們將在亞特蘭大的 ISPOR 會議上發表新數據,顯示開始使用 ORLADEYO 的病患在整體醫療資源使用(health care resource utilization)方面顯著下降,這項發現對付款方(payers)將非常有意義。

  • We are well positioned to provide frequent health economics -- health outcomes and economics updates with large and growing cohorts that already include hundreds of patients. These new data will further support the growth in customer demand for ORLADEYO for many years to come.

    我們具備良好條件,能以已包含數百名病患且持續擴大的大型隊列,頻繁提供健康經濟學——健康結果與經濟(health outcomes and economics)的最新資訊。這些新數據將進一步支持 ORLADEYO 在未來多年客戶需求的成長。

  • The increasing customer confidence that we're seeing in the US is also happening in the rest of the world. Patient growth in Europe was strong and consistent in the first quarter and recent launches in Spain and Italy are already adding to this trend. Finally, our BioCryst Japan team is now fully in place from the start of 2024, and we are encouraged by the early signs of their impact.

    我們在美國看到的客戶信心提升,也正在世界其他地區發生。第一季歐洲病患成長強勁且穩定,近期在西班牙與義大利的上市也已開始推動這一趨勢。最後,我們的 BioCryst 日本團隊自 2024 年初起已全面到位,我們對其早期影響的跡象感到鼓舞。

  • The overall trends in real-world evidence, customer confidence in patient growth continue to point to $800 million in peak US revenue with sustained peak global revenue of $1 billion.

    真實世界證據的整體趨勢、客戶信心與病患成長,持續指向美國營收高峰 8 億美元,以及可持續的全球營收高峰 10 億美元。

  • I'll now hand over to Helen to provide an update on our pipeline.

    接下來我把時間交給 Helen,提供我們產品線的最新進展。

  • Helen Thackray - Chief Research & Development Officer

    Helen Thackray - Chief Research & Development Officer

  • Thanks, Charlie. Our research and development teams are busier than ever as we are rapidly approaching our next major pipeline milestones, which include advancing multiple programs into the clinic starting later this year and filing for pediatric approval with ORLADEYO. Let's start there.

    謝謝你,Charlie。我們的研發團隊比以往任何時候都更忙碌,因為我們正快速接近下一個重要的產品線里程碑,包括自今年稍晚起推動多個計畫進入臨床,以及為 ORLADEYO 提交兒科適應症核准申請。我們就從這裡開始。

  • I'm pleased to share that we've completed enrollment in the pediatric trial with ORLADEYO, which includes extending dosing in children down to two years of age. This means we are on track to submit for pediatric registration as planned in 2025. It also means we are even closer to providing the first oral prophylactic therapy to children with HAE.

    我很高興分享,我們已完成 ORLADEYO 兒科試驗的受試者招募,其中包括將兒童用藥年齡下修至兩歲。這表示我們正按計畫於 2025 年提交兒科適應症註冊申請。這也意味著我們更接近為 HAE 兒童提供首個口服預防性治療。

  • It's been remarkable how quickly our pediatric has enrolled. We believe this reflects the demand for an oral therapy as prophylaxis of HAE attacks in children. It has the potential for this to be a transformative option for both children and their parents. A pediatric formulation made of granules that can be sprinkled on soft foods or taken with a glass of water. We are excited to be so close to achieving this goal of bringing ORLADEYO to children under 12, and we look forward to submitting for registration next year.

    我們的兒科試驗招募速度之快令人驚豔。我們相信這反映出市場對於以口服療法作為兒童 HAE 發作預防用藥的需求。這有潛力成為對孩子與其父母都具變革性的選擇。兒科劑型為顆粒,可灑在軟質食物上或配一杯水服用。我們很興奮能如此接近達成將 ORLADEYO 帶給 12 歲以下兒童的目標,並期待於明年提交註冊申請。

  • Turning to our next clinical program, our Factor D inhibitor, BCX10013, we continue to progress the ongoing proof of concept trial, and we expect to either partner or discontinue the program later this year as planned.

    接著談到我們下一個臨床計畫:我們的 Factor D 抑制劑 BCX10013。我們持續推進正在進行的概念驗證試驗,並預期如計畫於今年稍晚選擇合作夥伴或終止該計畫。

  • Up next, we have two pipeline programs that will enter the clinic within 18 months. These are BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema or DME. We are on track to begin a clinical trial with BCX17725 by the end of this year. This is a fusion protein with very high potency inhibition for KLK5 and has the potential to be a best-in-class product, providing disease-altering treatment for people with Netherton syndrome.

    接下來,我們有兩個管線計畫將在 18 個月內進入臨床。分別是用於 Netherton 症候群的 BCX17725,以及用於糖尿病黃斑水腫(DME)的 avoralstat。我們正按進度於今年底前啟動 BCX17725 的臨床試驗。這是一種融合蛋白,對 KLK5 具有極高效力的抑制作用,並有潛力成為同類最佳產品,為 Netherton 症候群患者提供可改變疾病進程的治療。

  • Netherton syndrome is a rare, lifelong genetic disorder that often presents in infancy with red, scaly, and inflamed skin. Patients require chronic care to protect the skin and monitor for lifelong susceptibility to inflammatory and atopic conditions. Netherton syndrome can be life-threatening, especially during infancy when neonates are vulnerable to dehydration and recurrent infections. Currently, there is no approved treatment for Netherton syndrome, and it's our goal to deliver a targeted therapy for these patients.

    Netherton 症候群是一種罕見、終身性的遺傳疾病,常在嬰兒期出現紅、脫屑且發炎的皮膚表現。患者需要長期照護以保護皮膚,並監測其終身對發炎性與異位性疾病的易感性。Netherton 症候群可能危及生命,尤其在嬰兒期,新生兒容易脫水並反覆感染。目前尚無核准的 Netherton 症候群治療,我們的目標是為這些患者提供具標靶性的療法。

  • Next into the clinic will be avoralstat, our plasma kallikrein inhibitor, in development for the treatment of diabetic macular edema or DME, which is on track to initiate a trial in patients next year. Our goal here is to improve vision in patients with persistent DME despite the use of VEGF inhibitors. At least a third of patients with DME have continuing symptoms and even worsening vision loss when treated with VEGF inhibitors, which may be because plasma kallikrein is a contributing cause of disease. The need for additional therapeutic options is real.

    下一個進入臨床的將是 avoralstat,我們的血漿激肽釋放酶(plasma kallikrein)抑制劑,正開發用於治療糖尿病黃斑水腫(DME),並按進度於明年在患者中啟動試驗。我們在此的目標是改善在使用 VEGF 抑制劑後仍持續存在 DME 的患者視力。至少三分之一的 DME 患者在接受 VEGF 抑制劑治療時仍有持續症狀,甚至視力喪失惡化,這可能是因為血漿激肽釋放酶是疾病的促成原因之一。對額外治療選項的需求確實存在。

  • We're working with Clearside to deliver avoralstat to the suprachoroidal space in the eye in order to achieve sufficient exposure in the right location to interrupt the pathophysiology of DME in the retina and stop swelling in the back of the eye. Based on the preclinical and safety data we accumulated with avoralstat when we studied it in the HAE program, we are in a position to move quickly into patients with DME with our first clinical trial next year, so we can evaluate for proof of concept directly in patients.

    我們正與 Clearside 合作,將 avoralstat 投遞至眼內的脈絡膜上腔(suprachoroidal space),以在正確位置達到足夠暴露量,進而中斷視網膜中 DME 的病理生理機制,並停止眼後段腫脹。基於我們在 HAE 計畫研究 avoralstat 時累積的臨床前與安全性資料,我們具備條件於明年迅速在 DME 患者中展開首次臨床試驗,以便直接在患者身上評估概念驗證。

  • Right behind these two programs, our discovery programs for targets across the complement system are also advancing. The three programs underway include our protein therapeutic complement inhibitor targeting all three pathways: the classical, lectin, and alternative pathways complement; and our oral C5 and oral C2 inhibitor small molecules. We are on track to have both the oral C5 inhibitor and the protein therapeutic multifunctional complement inhibitor advance into IND-enabling studies later this year.

    緊接在這兩個計畫之後,我們針對補體系統各靶點的探索性研發計畫也在推進。目前進行中的三個計畫包括:我們的蛋白質治療型補體抑制劑,可同時靶向三條途徑——經典途徑、凝集素途徑與替代途徑;以及我們的口服 C5 與口服 C2 抑制劑小分子。我們正按進度於今年稍晚讓口服 C5 抑制劑與蛋白質治療型多功能補體抑制劑進入 IND 支援性研究。

  • So in summary, we continue to progress well towards our goal of delivering inhibitors for every pathway in the complement system. Overall, the depth and breadth of our pipeline provides balance and great potential with a diversified set of molecules moving forward. This allows us to increase the likelihood that our pipeline today will produce our next drug in the market tomorrow. We are excited the pipeline is now advancing into the clinic with multiple programs.

    總結而言,我們持續朝著在補體系統每一條途徑都能提供抑制劑的目標穩健推進。整體來看,我們管線的深度與廣度提供了平衡性與高度潛力,並以多元化分子組合向前推進。這使我們能提高目前管線在未來產出下一款上市藥物的機率。我們對於管線如今以多個計畫推進至臨床感到振奮。

  • Next, I'll turn it to Anthony for a financial update.

    接下來,我把時間交給 Anthony 進行財務更新。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Thanks, Helen. You can find our detailed first quarter financials in today's earnings press release, and I'd like to call your attention to a few items.

    謝謝你,Helen。各位可在今日的財報新聞稿中找到我們第一季的詳細財務資訊,我想特別提醒幾個重點。

  • Total revenue for the quarter was $92.8 million, $88.9 million of which came from ORLADEYO with the remaining $3.9 million coming from RAPIVAB sales. That puts ORLADEYO trailing 12-month revenues at $346.4 million, with Q1 revenue increasing 30% over Q1 of 2023. Of the $88.9 million of global ORLADEYO revenue sales, $80 million came from US sales with the remaining $8.9 million or 10% coming from ex-US sales.

    本季總營收為 9,280 萬美元,其中 8,890 萬美元來自 ORLADEYO,其餘 390 萬美元來自 RAPIVAB 銷售。這使 ORLADEYO 過去 12 個月的營收達 3.464 億美元,且第一季營收較 2023 年第一季成長 30%。在 ORLADEYO 全球 8,890 萬美元的營收中,8,000 萬美元來自美國銷售,其餘 890 萬美元(或 10%)來自美國以外市場。

  • The 30% year-over-year increase in sales was primarily driven by the strong underlying patient growth that we have continued to see quarter-over-quarter. The $4 million improvement in Q1 performance versus our previous guidance of $85 million was primarily driven by the efforts of the commercial team to improve and accelerate the reauthorization process. That's $4 million that last year we would not have been able to capture until Q2, but this year, the team managed to accelerate the timing and achieve it from quarter one.

    銷售額年增 30% 主要由我們持續看到的強勁患者人數成長所帶動,且呈現逐季成長。第一季表現較我們先前 8,500 萬美元的指引改善 400 萬美元,主要來自商業團隊改善並加速再授權(reauthorization)流程的努力。這 400 萬美元在去年我們要到第二季才能認列,但今年團隊成功提前時點,於第一季即達成。

  • For Q2, we expect to achieve revenues of approximately $97 million, and as Charlie said, we've revised our full year revenue guidance to the higher end of the range between $390 million and $400 million. Operating expenses, not including noncash stock compensation, for the quarter were $93.6 million, an increase of $10.4 million over Q1 of 2023. Included in this are $1.3 million of onetime expenses related to the R&D structuring at the beginning of the year.

    第二季我們預期營收約為 9,700 萬美元;如 Charlie 所說,我們已將全年營收指引上修至 3.90 億至 4.00 億美元區間的較高端。本季營業費用(不含非現金股票薪酬)為 9,360 萬美元,較 2023 年第一季增加 1,040 萬美元。其中包含年初與研發(R&D)架構調整相關的一次性費用 130 萬美元。

  • Full year 2024 guidance for OpEx is unchanged, up between $365 million and $375 million. With revenue up $24 million year-over-year at $92.8 million and OpEx up $10.4 million year-over-year at $93.6 million, we continue to see improved margin accretion and our operating loss for the quarter, not including noncash stock comp was less than $1 million.

    2024 全年營業費用(OpEx)指引維持不變,介於 3.65 億至 3.75 億美元。在營收年增 2,400 萬美元至 9,280 萬美元、營業費用年增 1,040 萬美元至 9,360 萬美元的情況下,我們持續看到利潤率改善;本季營業虧損(不含非現金股票薪酬)低於 100 萬美元。

  • Cash at the end of the quarter was up $338.4 million, and net cash utilization for the quarter was $52.4 million. Q1 is historically our largest quarter of the year for cash utilization. For context, last year's Q1 was responsible for over 50% of total cash utilization for the entire year. Included in Q1, this year we had $3.2 million related to the R&D restructuring and $6.9 million related to royalty payments to OMERS. This is our first quarter of making such cash payments to OMERS, and as a reminder, while the royalties are considered a debt instrument for GAAP purposes that cannot be called and ultimately should be considered more the long-time liability than true debt.

    季末現金為 3.384 億美元,且本季淨現金使用額為 5,240 萬美元。第一季歷來是我們全年現金使用額最高的季度。作為參考,去年第一季占全年總現金使用額的 50% 以上。今年第一季包含與研發重整相關的 320 萬美元,以及支付給 OMERS 的權利金款項 690 萬美元。這是我們首次向 OMERS 進行此類現金支付;提醒各位,雖然就 GAAP 而言,該權利金被視為不可贖回的債務工具,但最終應更視為長期負債,而非真正的債務。

  • Additionally, with the revised guidance for full year ORLADEYO revenue, this will result in an improved blended royalty rate as more revenue will fall into the above $350 million tier where royalties are at a reduced rate of 7.5%. Cash utilization will decline in the remaining quarters of the year as it did last year, closer to an average of $10 million to $12 million per quarter, and we expect to end the year with above $300 million in cash.

    此外,隨著全年 ORLADEYO 營收指引上修,將帶來更佳的加權平均權利金率,因為更多營收將落在 3.5 億美元以上的級距,而該級距的權利金率降至 7.5%。如同去年,全年其餘季度的現金使用額將下降,接近每季平均 1,000 萬至 1,200 萬美元;我們預期年底現金將超過 3 億美元。

  • It's great to see the continuing strong performance of ORLADEYO. The commercial team did an outstanding job to improve our performance during the reauthorization process, an improvement that we'd hope to continue and build upon in next year's quarter one. This strength in revenue performance, supported by continued strong underlying patient demand, is what drives the revised full year revenue guide between $390 million and $400 million.

    很高興看到 ORLADEYO 持續展現強勁表現。商業團隊在再授權流程期間表現出色,成功提升了我們的業績;我們希望這項改善能在明年第一季延續並進一步擴大。在持續強勁的底層病患需求支持下,這樣的營收表現促使我們將全年營收指引上修至 3.90 億至 4.00 億美元。

  • And with full year OpEx remaining consistent for our guidance, we are in an even stronger position to deliver an operating profit this year when excluding noncash stock comp. We will continue on our planned path to near-term profitability that we shared earlier in the year, approaching quarterly cash flow and EPS positivity late next (technical difficulty) with full year cash flow and EPS positivity in 2026, all while continuing to advance our pipeline at full pace without the need to raise additional capital to get there.

    此外,在全年營運費用(OpEx)仍維持與指引一致的情況下,若排除非現金的股票薪酬費用,我們今年達成營業獲利的把握更高。我們將持續沿著今年稍早分享的近期獲利路徑前進,預期在明年稍晚接近單季現金流與每股盈餘(EPS)轉正(技術問題),並在 2026 年達成全年現金流與 EPS 轉正;同時,我們也將在不需要為此再募集額外資金的前提下,以全速推進我們的研發管線。

  • Operator, we'll now open it up for questions.

    接線員,現在我們開放提問。

  • Operator

    Operator

  • (Operator Instructions) Jessica Fye, JPMorgan.

    (接線員指示) Jessica Fye,摩根大通。

  • Nick Lenard - Analyst

    Nick Lenard - Analyst

  • Hey. This is Nick on for Jess. Congrats on the quarter and thanks for taking our questions. Two from us. You mentioned that the past two quarters have the most new prescription in the US since the first two quarters of the launch. Can you maybe provide some additional details on how that trend is looking so far in 2Q? And then maybe one on ex-US revenues. I know they came in at 10% this Q. You've talked about them being lumpier than the US. How should we expect that growth in the ex-US business this year? And at what point could that become less lumpy?

    嗨。我是 Nick,代 Jess 發言。恭喜本季表現,也謝謝讓我們提問。我們有兩個問題。你提到過去兩季在美國的新處方數是自上市前兩季以來最高。你能否提供一些補充細節,說明到目前為止在第二季(2Q)這個趨勢看起來如何?另外一個問題關於美國以外(ex-US)的營收。我知道本季約占 10%。你們也提過相較美國,ex-US 會比較不均勻(lumpy)。今年 ex-US 業務的成長應該如何預期?以及在什麼時點可能會變得比較不那麼不均勻?

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Charlie, why don't you take the first one and Anthony take the second one?

    Charlie,你先回答第一個,Anthony 回答第二個,好嗎?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Sure. I'm not going to comment yet on Q2, but other than two consecutive quarters of really great prescriptions, we've talked more -- we've talked before about all the market research that we do with physicians. They continue to expect to grow ORLADEYO prescriptions by about 30% over the next year. So we would expect this kind of demand to continue.

    好的。我現在還不評論第二季,但除了連續兩季處方表現非常亮眼之外,我們之前也談過我們對醫師所做的各項市場研究。他們仍預期未來一年 ORLADEYO 的處方量將成長約 30%。因此我們預期這類需求會持續。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Charlie, is it worth spending a little bit of time talking about the confidence that you're seeing in physicians and patients at this stage since the approval?

    Charlie,是否值得花一點時間談談自核准以來,你目前在醫師與病患端看到的信心程度?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Sure. Yeah. Like I said in my prepared remarks, as physicians have gained more and more experience in patients as well, they see that this drug is much more than just a convenient oral therapy. They see that ORLADEYO is a really effective therapy. And once they know that they can expect the high efficacy and the convenience together, it just gives them more confidence in prescribing. Physicians know that the majority of patients would prefer an oral therapy. And if they can get a really effective oral therapy, that makes them want to prescribe more. And I think that's what we're seeing now three-plus years into this launch.

    當然。是的。如同我在事先準備的發言中提到的,隨著醫師以及病患累積越來越多使用經驗,他們看到這款藥不僅僅是方便的口服療法。他們認為 ORLADEYO 是一個非常有效的治療。一旦他們知道可以同時兼具高療效與便利性,就會更有信心開立處方。醫師知道多數病患會偏好口服療法。如果能提供一個真正有效的口服療法,就會讓他們更願意開立。我認為這正是我們在上市三年多後所看到的情況。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • So Nick, with that confidence, we just don't see it letting up. Anthony?

    所以 Nick,基於這樣的信心,我們看不到它有減弱的跡象。Anthony?

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Yeah. So for ex-US, yeah. By the nature of how we sell into the ex-US markets, there's always going to be some lumpiness. Last year, we had about 11.5% of our total revenue coming from ex-US. I would expect something similar this year. I mean, if it's not there, it will be due to US overperformance as opposed to ex-US not being where we expect it to be. Ultimately, we would expect ex-US sales to continue to increase year-over-year until we hit peak.

    好的。關於 ex-US,是的。以我們在美國以外市場的銷售方式本質而言,營收總會有一些不均勻(lumpiness)。去年約有 11.5% 的總營收來自 ex-US。我預期今年也會是類似水準。如果比例沒有達到,那更可能是因為美國表現超預期,而不是 ex-US 未達我們的預期。最終,我們預期 ex-US 銷售會持續逐年成長,直到達到峰值。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • And then just to add to on the lumpiness. That really is -- it's just based on how we distribute. It has nothing to do with customer demand. What we're seeing is physicians are gaining the same kind of confidence that I described in the US, and we expect that to continue.

    另外再補充一下關於不均勻的部分。那其實—只是取決於我們的配送/分銷方式。與客戶需求無關。我們看到的是,醫師正在建立與我在美國所描述相同的信心,我們預期這會持續。

  • Nick Lenard - Analyst

    Nick Lenard - Analyst

  • Great. Thank you.

    很好。謝謝。

  • Operator

    Operator

  • Maury Raycroft, Jefferies.

    Maury Raycroft,Jefferies。

  • Maury Raycroft - Analyst

    Maury Raycroft - Analyst

  • Hi. Congrats on the quarter and thanks for taking my question. In your prepared remarks, you talked about your patient services team and investigations early in the first quarter that led to categorizing reauthorizations that's easy versus difficult. Can you talk more about what makes the reauthorizations easy versus difficult? And how you plan on building upon your learnings for the rest of the year with that?

    嗨。恭喜本季表現,也謝謝讓我提問。在你事先準備的發言中,你提到病患服務團隊在第一季初進行調查,進而將再授權分類為「容易」與「困難」。你能否多談談,什麼因素會讓再授權屬於容易或困難?以及你們打算如何把這些學習運用到今年剩餘時間?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Sure, Maury. With this kind of rare disease therapy, payors are always trying to make things a little bit difficult, but it's the kind of thing that I've described before, which is, they want a full patient history. They want lab tests. They want all the information they can get. And sometimes, when the payors already have this information, they can make it pretty quick to get to the reauthorization, but it's kind of in the payor's interest to throw as many speed bumps as possible. And so even if we've provided it before, sometimes they'll ask for it to be provided again.

    當然,Maury。對於這類罕見疾病療法,付款方(payors)總是會試著讓流程變得有點困難;但這跟我之前描述的一樣:他們想要完整的病患病史。他們想要實驗室檢測。他們想要盡可能多的資訊。有時候,當付款方已經掌握這些資訊時,再授權就能很快完成;但從付款方的角度,他們往往有動機設下越多「減速帶」越好。因此即使我們以前提供過,有時他們仍會要求再次提供。

  • And then there are some patients who just have more complicated histories, and those are the bigger challenges, but our teams had great success in getting all types of patients approved. So sometimes it's quick and sometimes it just takes a little bit of time. Everything that I see, though, gives me confidence about the 85% paid rate at peak, it's just going to take us a few years to get there.

    另外也有一些病患的病史更複雜,這些就是更大的挑戰;但我們的團隊在讓各類型病患獲得核准方面都非常成功。所以有時很快,有時只是需要多一點時間。不過我看到的一切都讓我對峰值時 85% 的給付率(paid rate)有信心,只是我們需要幾年時間才能達到。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • I think the other piece is Charlie made a decision a little over a year ago to change the model and improve this reimbursement and the support services around it, starting to see the fruit of that. And I think we'll continue to see that as this year progresses in future years. So it's a great, great signal. Great signal.

    我想另一個重點是,Charlie 在一年多前做了決定,改變模式並改善給付報銷以及相關支援服務;我們開始看到成果。我認為隨著今年推進以及未來幾年,我們會持續看到這些成果。所以這是一個非常、非常好的訊號。很好的訊號。

  • Maury Raycroft - Analyst

    Maury Raycroft - Analyst

  • Got it. And maybe just a quick question. If you can comment on the way to say you're seeing with gross to net. And with the price increase that you took in January, is that something that we should expect going forward for the next couple of years?

    了解。再問一個很快的問題。如果可以的話,請談談你們看到的總額到淨額(gross to net)的走勢。以及你們在一月進行的漲價,未來一兩年是否也應該預期會持續這樣做?

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • The first one, you take the second.

    第一個你回答,第二個你回答。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Yeah. On the GTN side, so for reimbursed product, we've historically at 15% to 20%. And much like last year, Q1 is at the higher end of that range, closer to 20%. For the remainder of the year, based on the speed at which Charlie's team got through the (inaudible) process, we'd expect it to come down and be at the lower end.

    好的。在 GTN 方面,對於已獲給付的產品,我們歷來大約在 15% 到 20% 之間。和去年類似,第一季位於區間高端,接近 20%。今年剩餘時間,基於 Charlie 團隊完成(聽不清)流程的速度,我們預期會下降並落在區間低端。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • And Maury, this year we did -- at the beginning of the year, we had a 5% price increase, and we expect to net about 3.5% of that. And as far as growth to the $800 million at peak in the US, all we would expect is very modest price increases as part of that build towards the $800 million.

    Maury,今年我們在年初進行了 5% 的漲價,預期淨實現約為其中的 3.5%。至於美國市場在峰值達到 8 億美元的成長,我們的預期只是會有非常溫和的漲價,作為逐步建立至 8 億美元的一部分。

  • Maury Raycroft - Analyst

    Maury Raycroft - Analyst

  • Got it. Thanks for taking my questions.

    了解。謝謝讓我提問。

  • Operator

    Operator

  • Tazeen Ahmad, Bank of America.

    Tazeen Ahmad,美國銀行。

  • Tazeen Ahmad - Analyst

    Tazeen Ahmad - Analyst

  • Hi, guys. Good morning and thanks for taking my questions. Can I ask about 1013. Any more color on when you expect to make a final decision on that asset? And are you going to be presenting any more data if you do intend to move forward with that? And then I just wanted to ask a question about guidance. And based on where you are still early in the year, is it possible that you could revise the upper end of guidance higher as the year progresses just based on trends that you're seeing so far? Thanks.

    嗨,各位。早安,謝謝讓我提問。我想問一下 1013。你們預期何時會對該資產做出最終決定?能否再多提供一些說明?如果你們打算推進,是否還會再公布更多數據?另外我也想問一下財測指引。鑑於目前仍在年初階段,依照你們迄今看到的趨勢,是否有可能在今年進行期間把指引區間的上緣往上調?謝謝。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah, on 10013, as we said at the beginning of the year, the goal is either to partner it or if we can't, then we'll stop the program. And so, the next thing that you'll likely hear is whether or not we've decided to partner the drug. And then on guidance, we've adjusted the bottom up in the range. And when we're confident to adjust it further, we'll let you know. But for right now, it's moving the bottom up.

    是的,關於 10013,正如我們在年初所說,我們的目標是要嘛為它尋找合作夥伴;如果做不到,我們就會停止該計畫。所以你們接下來很可能會聽到的消息,就是我們是否已決定為這個藥物尋求合作。至於指引,我們已把區間下緣上調。等我們有信心再進一步調整時,會再告訴大家。但目前就是把下緣往上移。

  • Operator

    Operator

  • Okay. Was there a follow-up to your question?

    好的。你還有追問嗎?

  • Tazeen Ahmad - Analyst

    Tazeen Ahmad - Analyst

  • I think both were answered. Thanks.

    我想兩個問題都回答到了。謝謝。

  • Operator

    Operator

  • Serge Belanger, Needham & Company.

    Serge Belanger,Needham & Company。

  • Serge Belanger - Analyst

    Serge Belanger - Analyst

  • Good morning. Thanks for taking my questions. Nice ORLADEYO quarter. I guess for Charlie, you mentioned two strong quarters of patient growth, exceeding the first two quarters of the launch. Can you give us just a little more color on that and maybe how it compares on a year-over-year basis? And then with the success of the reauthorization process, it sounds like we're not going to see the usual seasonality trends, but curious how you think about your long-term target of 85% paid scripts? Is that still the target? And does that move up the timeline to hit that target? Thanks.

    早安。謝謝讓我提問。ORLADEYO 這一季表現不錯。我想問 Charlie,你提到連續兩季病患成長強勁,超過上市初期前兩季。能否再多補充一些細節,並說明與去年同期相比如何?另外,重新授權流程的成功,聽起來我們可能不會看到以往常見的季節性趨勢;但我想了解你們如何看待長期目標「85% 付費處方」?這仍然是目標嗎?達成該目標的時間表是否因此提前?謝謝。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Thanks, Serge. So just to clarify one thing. The last two quarters were the best two quarters since the first two quarters of launch. So the first two quarters were just slightly better. But I think what it shows is that there was no just -- there's no bolus of patients early that we got and then demand falls. Demand is actually building over time as customers gain more confidence, like I was saying in one of my previous responses.

    謝謝你,Serge。我先澄清一點。最近兩季是自上市前兩季以來表現最好的兩季。也就是說,上市前兩季其實略好一些。但我認為這顯示並不是我們在初期拿到一波大量病患,之後需求就下滑。相反地,隨著客戶信心提升,需求其實是隨時間逐步建立起來的,就像我在先前回覆中提到的。

  • And then the 30% growth in revenue year-over-year, I think, kind of speaks for itself at this point in launch, to be growing that strongly is impressive. As far as the Q2 seasonality, as Anthony was saying, we would not expect as big a jump this year. We're guiding to $97 million in Q2, and we would expect that same trend, I think, in the future, where we're going to get more revenue in the first quarter just through more effective reauthorization processes.

    另外,營收年增 30%,我想在目前這個上市階段已經很能說明問題;能有這麼強的成長很令人印象深刻。至於第二季的季節性,如同 Anthony 所說,我們預期今年不會有那麼大的跳升。我們對第二季的指引是 9,700 萬美元;我認為未來也會看到類似趨勢,也就是第一季會因更有效率的重新授權流程而帶來較多營收。

  • And then as far as the growth to 85%, that underlying improvement in the rate of paid, as I commented before, it's going to take us some years to get there. All of these improvements that we're making with adding to the team, getting better and better each year going through this process, tells me we're going to get there. And the bigger jump, the bigger opportunity would be next year with the IRA rolling in and hopefully, that helps us get more Medicare patients to paid therapy as the maximum out-of-pocket goes to $2,000. But the overall growth to 85% is going to be a multiyear process.

    至於付費率提升到 85%,如我先前評論,這需要幾年時間才能達成。我們透過擴編團隊、每年在流程中持續精進等各項改善,讓我相信我們會做到。而更大的跳升、也就是更大的機會,可能會在明年,隨著 IRA 開始生效;希望當最高自付額降至 2,000 美元時,能幫助我們讓更多 Medicare 病患轉為付費治療。但整體提升到 85% 仍會是一個多年期的過程。

  • Serge Belanger - Analyst

    Serge Belanger - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Brian Abrahams, RBC Capital Markets.

    Brian Abrahams,RBC Capital Markets。

  • Unidentified Participant

    Unidentified Participant

  • Hi everyone. This is [Nevin] on for Brian. Congrats on a good quarter. I just had a couple of questions on SG&A and some of your strategic initiatives to maybe accelerate some of that. Can you speak to some of those, whether you have any sales acceleration initiatives planned to drive any increased uptake either in the US or ex-US as well with some of the expansions in some of the geographies ex-US?

    各位好。我是 [Nevin],代 Brian 提問。恭喜本季表現不錯。我有幾個關於 SG&A 以及你們一些策略性舉措的問題,這些舉措可能會加速某些進展。能否談談其中一些內容?例如你們是否規劃任何銷售加速計畫,以推動美國或美國以外市場的採用提升,尤其是在美國以外一些地區擴張的情況下?

  • And then are you -- in fourth quarter, you had guided towards increase in SG&A of about $20 million. Is that still the case for 2024? And could we expect the patient services team to be in place throughout the year? Or would this be something that you would add to the team seasonally as well near the end of the year, maybe add to the team to help with the rep at the beginning?

    另外,你們在第四季曾指引 SG&A 將增加約 2,000 萬美元。2024 年仍是如此嗎?而病患服務團隊會在全年都到位嗎?還是你們也會在年底附近做季節性增員,例如在年初協助重新授權(rep)時再擴編?

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Charlie, maybe just talk just talk in general about where you're at with the build of your team and then Anthony can talk directly on some of these things.

    Charlie,你或許先概括談談團隊建置的進度,然後 Anthony 再針對其中一些問題直接回覆。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Sure. And I'll also talk about some of those specific initiatives that Nevin asked about. So the investments we made last year were to, like I said, just to improve the efficiency and effectiveness. We're always looking to make improvements at the margin. If we see an opportunity, we'll add a little bit. We don't expect any major adds to our team at this point. It will just be kind of marginal additions, particularly as our patient base grows.

    好的。我也會談談 Nevin 問到的一些具體舉措。我們去年所做的投資,如我所說,是為了提升效率與效能。我們一直在尋找邊際上的改善空間。如果看到機會,我們會再多投入一點。但目前我們不預期會對團隊做任何重大增員。只會是一些小幅度的增補,特別是隨著病患基礎成長。

  • Our patient services team will grow slightly as the patient base grows. But that's not a seasonal growth. That's kind of long-term investment in the team. And then we're always looking to strengthen the brand with additional data and additional initiatives. So we'll continue to look for those opportunities, like the real-world evidence that I described in my prepared remarks.

    我們的病患服務團隊會隨著病患基礎成長而小幅擴大。但那不是季節性的成長。那更像是對團隊的長期投資。此外,我們也一直在透過更多數據與更多舉措來強化品牌。因此我們會持續尋找這些機會,例如我在事先準備的發言中提到的真實世界證據。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • In terms of where we are versus what we had talked about previously, I'd expect about a 20% increase in SG&A year-over-year. But again, most of that is broken down into kind of the full-year impact for the increases that Charlie's team did where you had partial impact last year. And then for the ex-US side, yeah, there'll be smaller increases. But I would think about it far more in terms of how the team is focusing on the idea of margin accretion.

    就我們目前的狀況相較於先前所談,我預期 SG&A 年增約 20%。但再次強調,其中大部分是拆解為全年化影響:也就是 Charlie 團隊所做的增員在去年只有部分年度影響。至於美國以外市場,是的,會有較小幅度的增加。但我會更從「團隊如何聚焦於提升利潤率(margin accretion)」的角度來看。

  • So the investments that we are making, the investments that we continue to make, are going to be significantly less than the revenues that are generated as we get towards peak. And so, I'm really excited to start to see that margin accretion and its role in getting us to and through profitability.

    我們正在做的投資、以及持續進行的投資,將會明顯低於我們在邁向峰值時所帶來的營收增量。因此,我非常期待開始看到利潤率提升,以及它在帶領我們達到並跨越獲利門檻上的作用。

  • Unidentified Participant

    Unidentified Participant

  • Got it. Thank you. Just wanted to clarify, you mentioned 20% increase year-over-year in SG&A --

    了解。謝謝。我想確認一下,你剛提到 SG&A 年增 20%——

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Sorry. $20 million.

    抱歉,是 2,000 萬美元。

  • Unidentified Participant

    Unidentified Participant

  • $20 million? Okay. Thank you.

    2,000萬美元?好的。謝謝。

  • Operator

    Operator

  • Liisa Bayko, Evercore ISI.

    Liisa Bayko,Evercore ISI。

  • Liisa Bayko - Analyst

    Liisa Bayko - Analyst

  • Hi. Congrats on a good quarter. Just a couple of points of clarification. For your outside like OUS revenue, and you said it was about 10%, does that include the Japanese royalty or no?

    嗨。恭喜本季表現不錯。我有幾點想釐清。關於你們的海外(OUS)營收,你說大約是 10%,那其中有包含日本的權利金嗎?還是沒有?

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Yeah, it does include the Japanese royalty.

    有,包含日本的權利金。

  • Liisa Bayko - Analyst

    Liisa Bayko - Analyst

  • Okay. And then what were gross to net in the quarter? And maybe you can comment on how they'll evolve over the course of this year?

    好的。那本季的 gross-to-net 是多少?也請你們談談今年接下來它會如何變化?

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Yeah. So gross to net on the reimbursed side here in the US closer to 20%. So again, historically guiding to 15% to 20%. That includes the reauthorization impact, the co-pay assistance impacts, the reset of that and then moving towards the latter part of the year, it will normalize closer into that 15% range, but it will average us out for the year in the 15% to 20%.

    好的。在美國這邊、屬於給付(reimbursed)端的 gross-to-net 大約接近 20%。我們過去的指引一向是 15% 到 20%。這其中包含重新授權(reauthorization)的影響、共付額補助(co-pay assistance)的影響、相關重置,以及到了今年後段會正常化、回到更接近 15% 的區間;但全年平均會落在 15% 到 20%。

  • Liisa Bayko - Analyst

    Liisa Bayko - Analyst

  • Okay. And then other revenue, does that -- how much of that is Japanese revenue and how much of that is Rapivab or other stuff? Could you clarify.

    好的。那其他營收(other revenue)方面,其中有多少是日本的營收、多少是 Rapivab 或其他項目?可以釐清一下嗎?

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah, revenue is all Rapivab.

    好的,其他營收全部都是 Rapivab。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Yeah. So $88.9 million of it is ORLADEYO and then #3.9 million is Rapivab. If you're asking for a specific split of product versus other revenue, we don't generally give that. But, listen, Rapivab revenue for the most part is inconsequential, especially as ORLADEYO revenue's getting to the point where it's almost $100 million a quarter.

    對。其中 8,890 萬美元是 ORLADEYO,另外 390 萬美元是 Rapivab。如果你問的是產品營收(product)與其他營收(other revenue)的更細分拆分,我們通常不會提供。不過坦白說,Rapivab 的營收大多不具重要性,尤其是 ORLADEYO 的營收已經快到每季接近 1 億美元的水準。

  • Liisa Bayko - Analyst

    Liisa Bayko - Analyst

  • Okay. But that doesn't include Japanese revenue in that line, yeah?

    了解。但那一行裡面不包含日本營收,對吧?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • The $88.9 million does. Japanese.

    8,890 萬美元那個數字有包含。日本的。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • The $88.9 million does include ORLADEYO -- sorry, Japanese ORLADEYO revenue.

    8,890 萬美元確實包含 ORLADEYO——抱歉,是日本的 ORLADEYO 營收。

  • Liisa Bayko - Analyst

    Liisa Bayko - Analyst

  • Okay. Got it. And then any inventory changes in the quarter?

    好的。了解了。那本季有任何庫存變動嗎?

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • No. We continue to be laser focused on ensuring that we have significant quantities. The cost of sales is really, really low. And so, our team does a great job of making sure that we have enough for all of our territories.

    沒有。我們持續非常專注,確保我們有充足的供應量。銷貨成本其實非常、非常低。因此我們的團隊做得很好,確保所有市場區域都有足夠的供貨。

  • Liisa Bayko - Analyst

    Liisa Bayko - Analyst

  • Okay. Great. And then just finally, can you maybe just talk about the pediatric expansion opportunity and just kind of qualify that in terms of potential upside?

    好的。很好。最後一個問題,你能否談談兒科適應症擴張的機會,並就潛在上行空間做個定性說明?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Sure. I think the first point is, as Helen pointed out, there's just a huge need amongst kids to have an oral therapy. It's not just the kids, it's the parents. So I think that this is a very highly anticipated product launch when it comes from the market. We think there are about -- in the US, about 500 kids who may be in the consideration for prophylactic therapy. It's an evolving space because there haven't been prophy therapies available for kids before and then to have the first oral, it will change.

    當然。我想第一點是,如同 Helen 指出的,孩子對口服治療有很大的需求。不只是孩子,家長也是。所以我們認為,從市場角度來看,這會是一個非常受期待的產品上市。我們估計在美國大約有 500 位兒童可能會被納入預防性治療(prophylactic therapy)的考量。這個領域仍在演變,因為過去兒童並沒有可用的預防性治療,而第一個口服選項的出現將帶來改變。

  • So it's up to 500 patients for prophylaxis. And then the other piece is just the halo effect, which is another way to introduce ORLADEYO to physicians and the families to patients. And so, we expect it to be important for us.

    所以預防用藥(prophylaxis)最多大約 500 位病人。另外一個面向是所謂的光環效應(halo effect),也就是另一種把 ORLADEYO 介紹給醫師與家庭、病人的方式。因此我們預期這對我們會很重要。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • And as Helen said in her remarks, when you enroll faster than you thought, that's usually a really good sign that you've got something that people want, and that's exactly what happened.

    而且如同 Helen 在發言中提到的,當收案速度比預期更快時,通常是人們確實想要這個產品的很好的訊號,而我們的情況正是如此。

  • Liisa Bayko - Analyst

    Liisa Bayko - Analyst

  • Okay. Great. Thanks.

    好的。很好。謝謝。

  • Operator

    Operator

  • Stacy Ku, TD Cowen.

    Stacy Ku,TD Cowen。

  • Stacy Ku - Analyst

    Stacy Ku - Analyst

  • Hey. Thanks so much for taking our questions and congratulations on the progress. So we have a few follow-ups. So first, regarding your Q1 outperformance. What do you think is contributing to this new prescription growth, just characterize these patients a bit more? Is it coming from new prescribers versus current prescribers, just from kind of your patient activation and activities? That's the first question.

    嗨。非常感謝回答我們的問題,也恭喜你們的進展。我們有幾個追問。首先,關於你們第一季表現超預期。你認為是什麼因素帶動了新處方的成長?能否再多描述一下這些病人的特徵?這是來自新的開立醫師,還是既有開立醫師;或是來自你們的病人啟動(patient activation)與相關活動?這是第一個問題。

  • And then the second is around your long-term expectations for the Japanese launch of ORLADEYO. Can you just speak a little bit more about what you're seeing so far in early days and how you feel comfortable kind of long term for that opportunity?

    第二個問題是關於 ORLADEYO 在日本上市的長期展望。你能否多談一些目前在上市初期看到的情況,以及你們對這個機會的長期信心?

  • And then last, just on 10013. For the partnership, is the team waiting for the full 24-week results before engaging in discussions? And just to confirm, you all would still be getting those results in the middle of 2024, but you do not anticipate disclosing data to the Street? Thanks so much.

    最後是關於 10013。就合作夥伴而言,團隊是否會等到完整的 24 週結果出來後才開始洽談?另外確認一下,你們仍會在 2024 年年中拿到結果,但不預期對外(對市場)揭露數據,對嗎?非常感謝。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Hi, Stacy. So the first question, just in terms of the color on the new growth. It's very similar to what we've seen before. So we're getting prescriptions from existing prescribers. We're always adding new prescribers, as more become aware of ORLADEYO and gain confidence. The mix of patients is also very similar. The roughly 50% switching from other prophy and the other 50% best we can tell being naive to prophylactic therapy. So very consistent and, as I mentioned earlier, consistent to what physicians expect to do in the future. They see a lot more growth coming over the next year.

    嗨,Stacy。先回答第一個問題,關於新成長的補充說明。這和我們之前看到的非常相似。我們持續從既有開立醫師那裡獲得處方。同時也一直在增加新的開立醫師,因為更多人開始認識 ORLADEYO 並建立信心。病人組成也非常類似。大約 50% 是從其他預防用藥(prophy)轉換過來,另外 50% 依我們所能判斷是過去未使用過預防性治療(prophylactic therapy)的病人。因此非常一致,而且如我先前提到的,也符合醫師對未來行為的預期。他們認為未來一年還會有更多成長。

  • As far as Japan, we think still that there are fewer than 1,000 patients who have been identified in a market that could be 2,500 to even 3,000 HAE patients. So what the team is focused on right now is driving use of prophylaxis and oral prophylaxis within the diagnosed patient community and just building awareness about ORLADEYO.

    至於日本,我們仍認為目前被辨識出的病人不到 1,000 位,但整體市場可能有 2,500 甚至 3,000 位 HAE 病人。因此團隊目前的重點,是在已確診的病人族群中推動預防用藥的使用、以及口服預防用藥的使用,同時提升對 ORLADEYO 的認知。

  • Longer term, we think that as we're there with ORLADEYO, other manufacturers are there with other prophylaxis products, there will be more patient diagnosis. And so, we expect this to be a growing market for the next 5 or 10 years. We're very, very enthusiastic about the opportunity in Japan.

    從更長期來看,我們認為當我們以 ORLADEYO 進入市場、其他廠商也以其他預防產品進入市場後,病人的診斷數會增加。因此我們預期這將會是一個在未來 5 到 10 年持續成長的市場。我們對日本的機會非常、非常樂觀。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • And then, Stacy, on 10013, yes, we expect the data in the middle of this year. But what matters since we're not advancing it, we're seeking a partner to advance. It's what do they think about the data at the end of the day. And so, that's where we'll focus our attention.

    接著,Stacy,關於 10013,是的,我們預期會在今年年中拿到數據。但由於我們不會自行推進,而是尋找合作夥伴來推進,真正重要的是合作夥伴最終如何看待這些數據。因此我們會把重點放在那裡。也就是我們會把注意力集中在這一點上。

  • Stacy Ku - Analyst

    Stacy Ku - Analyst

  • Understood. Thank you so much.

    了解。非常感謝。

  • Operator

    Operator

  • (Operator Instructions) Gena Wang, Barclays.

    (接線員指示) Gena Wang,Barclays。

  • Gena Wang - Analyst

    Gena Wang - Analyst

  • Thank you. Maybe just one regarding the Japan since we have quite a few questions on Japan market. What is the price there? Is that also a 30% to 50% discount of the US price relative -- like similar to Europe price? And the second question is regarding the pediatric trial. I noticed it is a single-arm study. What data could be approvable based on FDA feedback?

    謝謝。或許再問一個關於日本的問題,因為我們對日本市場有不少提問。那邊的價格是多少?是否也像歐洲一樣,相對於美國價格有 30% 到 50% 的折扣?第二個問題是關於兒科試驗。我注意到這是一個單臂研究(single-arm study)。根據 FDA 的回饋,哪些數據可以作為核准依據?

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Charlie, you take Japan price and Helen take the --

    Charlie,你來回答日本定價,Helen 來回答--

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Gena, the Japanese price is actually the second highest price -- ORLADEYO price in the world. So at the moment -- and then, of course, it's subject to exchange rate variation. But at the moment, it's close to $200,000 per year. So it's higher than our European prices.

    Gena,日本的價格其實是全球 ORLADEYO 第二高的價格。所以目前——當然也會受到匯率波動影響。但就目前而言,每年接近 20 萬美元。所以高於我們在歐洲的價格。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • And then, Helen.

    接著,Helen。

  • Helen Thackray - Chief Research & Development Officer

    Helen Thackray - Chief Research & Development Officer

  • Question on the pediatric trial. It is a single arm, and that's fairly standard now for what's called extrapolation of the data. The point is to match exposures in the pediatric population with the exposures that are known to be effective in the adult population. So it's safety and PK, and that's what we'll really be submitted to the agency.

    關於兒科試驗的問題。這是一個單臂試驗,而這在所謂的資料外推(extrapolation)上,現在相當標準。重點是讓兒科族群的暴露量與已知在成人族群有效的暴露量相匹配。因此主要是安全性與藥物動力學(PK),而這也將是我們真正提交給主管機關的內容。

  • Gena Wang - Analyst

    Gena Wang - Analyst

  • I noticed you do have, also, attack rate collection. Will FDA also consider that data point, any like, say, threshold that you have to achieve?

    我注意到你們也有收集發作率(attack rate)。FDA 也會考量這個資料點嗎?例如你們必須達到某個門檻之類的?

  • Helen Thackray - Chief Research & Development Officer

    Helen Thackray - Chief Research & Development Officer

  • So attack rate's always collected when you're following patients, and we know the patient is doing well. That will be submitted as part of the data set, but the decision will be based on safety and the exposure.

    在追蹤病患時,發作率一向都會被收集,而且我們知道病患狀況良好。這會作為資料集的一部分提交,但決策將以安全性與暴露量為依據。

  • Gena Wang - Analyst

    Gena Wang - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • Francois Brisebois, Oppenheimer.

    Francois Brisebois,Oppenheimer。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Hi. Thanks. In terms of the pediatric importance here, you talked about up to 500 patients, but is there a scenario where you'd ever expect the patient to -- a pediatric to be on this and then turn into an adult and maybe change treatment option? Just wondering too if you can remind us all of the competition on the pediatric front.

    嗨。謝謝。就兒科的重要性而言,你們提到最多可達 500 名病患,但是否存在某種情境:兒科病患使用這個藥,之後長大成成人,可能會改變治療選項?另外也想請你們提醒大家,在兒科方面的競爭態勢是什麼。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • I think we -- what we would see is that patients who -- kids that need to start on prophylaxis and oral is going to be the best option for them just for obvious reasons. And this is a lifelong disease. So we think there's an opportunity for these kids to be on ORLADEYO for a very long period of time. And then as I mentioned earlier, just the family aspect of it too as a genetic disease. Usually, there is a parent or often a sibling, other family members in the household. And so, it's an opportunity for whole families to become more aware of the benefits of ORLADEYO. So we would expect them to stay on for the long term.

    我想我們——我們會看到的是,需要開始預防性治療的病患——對孩子來說,口服會是最佳選擇,原因很明顯。而且這是一種終身疾病。所以我們認為,這些孩子有機會在很長一段時間內使用 ORLADEYO。另外如我先前提到的,這也是遺傳疾病,還牽涉到家庭層面。通常家中會有父母,或常見的是兄弟姊妹,以及同住的其他家人。因此,這也是讓整個家庭更了解 ORLADEYO 益處的機會。所以我們預期他們會長期持續使用。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • I understood. Thank you.

    了解。謝謝。

  • Operator

    Operator

  • Jon Wolleben, JMP Securities.

    Jon Wolleben,JMP Securities。

  • Jon Wolleben - Analyst

    Jon Wolleben - Analyst

  • Hey. Thanks for taking the question. One on your market research, which has been seemingly accurate in the past. When you ask about prescribing in the next 12 months, wondering if you actually ask longer term as well about ultimate usage how that factors into your growth projection? Then also, it seems to be reflective of the uptake we're seeing. Do you ever have to expand who you're asking and what you're asking about to get more insight into what the trajectory looks like three, four years down the line?

    嘿。謝謝讓我提問。有一題關於你們的市場調查,過去看起來相當準確。當你們詢問未來 12 個月的處方情況時,想知道你們是否也會詢問更長期、最終使用量等,並將其如何納入成長預測?另外,這似乎也反映了我們看到的採用速度。你們是否會需要擴大受訪對象或調整提問內容,以便更深入了解未來三、四年的走勢?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Yeah. Thanks for the question, Jon. We absolutely do look at that longer term and ask them about the longer term. The growth in the next 12 months, that's the quarterly survey that we do with 60 to 100 physicians every quarter. Then we use that information plus other studies once a year to build a much longer-term model where we also incorporate everything that might come in the future, and we ask physicians their opinions of those products, what they think they will use. And then that all goes into a much larger market forecasting model to predict the future. It was very accurate in our first year of launch. And every year, our team updates this model.

    是的。謝謝你的問題,Jon。我們確實會看更長期,也會詢問他們對更長期的看法。未來 12 個月的成長,是我們每季進行一次的調查,每季訪問 60 到 100 位醫師。接著我們會使用這些資訊,再加上每年一次的其他研究,建立更長期的模型;同時也會把未來可能出現的一切納入,並詢問醫師對那些產品的看法、他們認為會如何使用。然後這些都會納入更大型的市場預測模型,用來預測未來。在我們上市的第一年,這個模型非常準確。而且每一年,我們的團隊都會更新這個模型。

  • And so we have a lot of confidence in our future predictions. And it is -- that is where our $1 billion peak revenue comes from. It comes from that model that incorporates all of the forward-looking market research.

    因此我們對未來的預測非常有信心。而且——我們所說的 10 億美元峰值營收就是從那裡來的。它來自這個納入所有前瞻性市場研究的模型。

  • Jon Wolleben - Analyst

    Jon Wolleben - Analyst

  • And then when this year do you guys do that annual revamp? And do you -- will you guys let us know the results?

    那你們今年會在什麼時候做年度更新?以及你們——會把結果告訴我們嗎?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • We will let you know if anything changes. We do it once a year around the middle of the year. And yeah, our goal is to be accurate in all of our forecasting. So if we see anything different, we'll definitely let you know.

    如果有任何變化,我們會告訴大家。我們每年做一次,大約在年中。是的,我們的目標是在所有預測上都保持準確。所以如果我們看到任何不同之處,一定會讓你們知道。

  • Jon Wolleben - Analyst

    Jon Wolleben - Analyst

  • Got it. Thanks, Charlie.

    了解。謝謝,Charlie。

  • Operator

    Operator

  • Chris Raymond, Piper Sandler.

    Chris Raymond,Piper Sandler。

  • Chris Raymond - Analyst

    Chris Raymond - Analyst

  • Thanks for squeezing me in. Jon, you've been pretty open in the past when folks have asked you guys about strategic interest and sort of inbound interest. And I think it's pretty clear now, by now, that there's a lot of buoyancy here, if you will, for maybe lack of a better word to ORLADEYO's uptake. I guess any discernible change in terms of frequency or maybe tenor of the inbound calls that you guys have had from strategics? Thanks.

    謝謝把我排進來。Jon,你們過去在大家問到策略性興趣、以及外部主動接觸(inbound interest)時,一直都很坦率。而且我想現在很清楚,ORLADEYO 的採用動能相當強——如果可以這麼說的話,暫時找不到更好的詞。我想問的是,策略方打進來的電話,在頻率或語氣/調性上,有沒有任何可辨識的變化?謝謝。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah, Chris, I mean, you know I can't talk about specifics and volume or changes. But the answer about our willingness to entertain those remains unchanged. We're a public company, and we have shareholder interest in our minds. And if someone is interested, we'll take the call. So no change there.

    是的,Chris,我的意思是,你知道我不能談具體內容、數量或變化。但我們願意考慮這類事情的立場並沒有改變。我們是一家上市公司,我們會把股東利益放在心上。如果有人有興趣,我們會接聽電話。所以這方面沒有改變。

  • Chris Raymond - Analyst

    Chris Raymond - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • This concludes our question-and-answer session. I would like to turn the conference back over to Jon Stonehouse for any closing remarks.

    問答環節到此結束。我想把電話會議交回給 Jon Stonehouse,請他做結語。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah. Thanks again for your interest in our company. We are off to a really, really good start to this year, and we're super excited where this will lead us to in terms of ORLADEYO trajectory and advancing the pipeline. So we're focused on continuing this momentum throughout the year and look forward to updating you as we have new information. Have a great day.

    是的。再次感謝各位對我們公司的關注。今年我們有一個非常、非常好的開局,我們也非常期待這將把我們帶往何處——就 ORLADEYO 的發展軌跡以及推進研發管線而言。因此我們專注於在今年持續這股動能,並期待在有新資訊時向各位更新。祝各位有美好的一天。

  • Operator

    Operator

  • The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

    本次電話會議到此結束。感謝各位參加今天的簡報。您現在可以掛線。